Surgvision

Kempen is proud to announce it has advised SurgVision on its sale to Bracco

• Bracco has entered into an agreement with the shareholders of SurgVision to acquire 100% of the shares in SurgVision for an undisclosed consideration
• This transaction highlights the sector expertise of Kempen’s Life Sciences and Healthcare team and its key role as financial advisor in cross-border M&A transactions in the sector

• Founded in 2013 as a spin-off of the Technical University of Munich and funded by BioGeneration and DFZ Participaties
• Specialised in developing fluorescence image guided surgery platform solutions using high-definition cameras and tracers
• Its innovative products have the potential to address the current impact of positive resection margins in breast conserving surgery

• Bracco is one of the world’s leading companies in diagnostic imaging, with over 3,400 employees and EUR 1.3bn in annual revenues
• The company has a portfolio of products, injectors and solutions for diagnostic applications such as X-ray imaging (including CT-scanning), MRI, contrast enhanced ultrasound, and nuclear medicine
• Bracco is privately held and based in Italy, operating in over 90 countries worldwide